This talk will highlight not only the promise of clinical genomics and personalized medicine in cancer drug development but will also highlight the challenges, such as ability to obtain biopsy material for analysis (especially repeat biopsies), tumor heterogeneity, assay robustness and availability, cost, privacy, and development of resistance.